Dr Patrick Vallance
Outgoing President, R&D
Dr Patrick Vallance - download image (JPG)
Patrick joined GSK in 2006 as Head of Drug Discovery and was subsequently appointed Senior Vice President, Medicines Discovery and Development. He has been a member of GSK’s Corporate Executive Team since 2010 and was appointed President, R&D in January 2012. Patrick joined the GSK Board on 1 January 2017.
In November 2017, Patrick announced his intention to leave the company to become the UK Government’s Chief Scientific Adviser. He will leave GSK at the end of March 2018.
Prior to joining GSK, Patrick was a clinical academic and, as Professor of Medicine, led the Division of Medicine at University College London. He has over 20 years’ experience of research clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999, and as a Fellow of The Royal Society in 2017.
Patrick is a Non-Executive Director of Genome Research Limited and UK Biobank.
Find out more
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Discover our latest financial performance announcement and search for historical quarterly results materials
Board of Directors
The Board of Directors is responsible for the group's system of corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance.
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business